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Bisphosphonates-related Osteonecrosis of the Jaw (BRONJ) has been reported with increasing frequency in literature over last
years, but its therapy is still a dilemma. One hundred ninety patients aﬀected by BRONJ were observed between January 2004
and November 2011 and 166 treated sites were subdivided in ﬁve groups on the basis of the therapeutical approach (medical
or surgical, traditional or laser-assisted approach, with or without Low Level Laser Therapy (LLLT)). Clinical success has been
deﬁned for each treatment performed as clinical improvement or complete mucosal healing. Combination of antibiotic therapy,
conservative surgery performed with Er:YAG laser and LLLT applications showed best results for cancer and noncancer patients.
Nonsurgical approach performed on 69 sites induced an improvement in 35 sites (50.7%) and the complete healing in 19 sites
(27.5%), while surgical approach on 97 sites induced an improvement in 84 sites (86.6%) and the complete healing in 78 sites
(80.41%). Improvement and healing were recorded in 31 (81.5%) and 27 (71.5%) out of the 38 BRONJ sites treated in noncancer
patients and in 88 (68.75%) and in 69 (53.9%) out of the 128 in cancer patients.
1.Introduction
Bisphosphonates-related osteonecrosis of the jaws (BRONJ)
management is controversial: there are no evidence-based
guidelines in the literature associated with good results
for a long-term follow-up, in particular regarding surgical
procedures [1]. The main purposes of each treatment are to
reducepainandtocontrolinfectionandslowtheprogression
of the disease, taking into account as main target the
eradicationofBRONJpromotingthecompletehealing.Most
of the authors privilege a noninvasive approach especially
for asymptomatic stages of BRONJ (Stage I in Ruggiero’s





variable from 17.3–17.6% for medical therapy or surgical
debridement to 46.3% for free ﬂap or surgical resection
procedures [13].
Cliniciansshouldalwayscarefullyconsiderthepossibility
of extensive surgery in oncological patients because of
general status and life expectancy. One of the exclusion
criteria was contraindications for surgery under general
anaesthesia: this element appears to be an important limit to
surgicalprocedureandconﬁrmsthechoiceforearlyminimal
invasive surgical therapy in stages I and II of BRONJ.
The widespread variant of BRONJ (stage III), in partic-
ular those with mandibular fractures, requires bone resec-
tion with extension to apparently healthy margins such as
bleeding points and normal colour of bone surfaces. On the
basis of BRONJ pathogenesis, many authors recommend a
largeresectionbecauseaninsuﬃcienteliminationofnecrotic
material may result in a recurrence of bone exposure.
The aim of this retrospective study is to present our
experience in a wide number of patients treated with2 Journal of Osteoporosis
Table 1: Baseline data of patients: BRONJ stage according to Ruggero’s classiﬁcation, gender distribution, age, and primary disease; BM:
bone metastasis, MM: multiple myeloma, OP: osteoporosis and/or rheumatoid arthritis.
BRONJ Stage Patients number Gender Mean age ± SD Primary disease
BM MM OP
Stage I 34 Female 26 66.3 ±11.41 5 9 1 0
Male 8
Stage II 126 Female 92 67.9 ±9.15 7 4 3 2 6
Male 34
Stage III 30 Female 20 65.5 ±12.21 3 1 0 7
Male 10
diﬀerent kinds of surgical and nonsurgical approaches based
or not on the use of laser-assisted techniques: the rationale
to use laser with low dosages is the biostimulating eﬀect
reported in literature on both bone and soft tissues.
2.MaterialandMethods
One hundred and ninety patients (52 males, 138 females;
62 with multiple myeloma (MM), 85 with bone metas-
tasis (BM), and 43 with osteoporosis (OP), mean age
67.3 ±10 years) aﬀected by BRONJ were evaluated at the
Unit of Oral Pathology and Medicine and Laser-Assisted
Surgery of the University of Parma, Italy, between January
2004 and November 2011 (Table 1).
At the time of BRONJ diagnosis, mean duration of BPT
was 26 ± 20 months (ranging between 3 and 72 months)
for cancer patients and 90 ± 40 months (ranging between
24 and 144 months) for noncancer patients. Thirty-nine
patients (20.5%) were smokers, 22 (11.5%) had diabetes,
and 125 patients (65.7%) received long-term corticosteroid
treatments (Table 2).
Among the 43 “osteoporotic patients,” 2 were treated
for rheumatoid arthritis, 39 for osteoporosis, and 2 for
both rheumatoid arthritis and osteoporotic, disease; corti-
costeroids were used in both the patients with rheumatoid
arthritis, in 15 out of 39 osteoporotic patients and in 1 out of
2 patients with osteoporosis an rheumatoid arthritis.
One hundred twenty out of 190 patients (63.2%) had
mandibular involvement, 53 out of 190 (27.9%) had BRONJ
in the maxilla, and 17 out of 190 patients (8.9%) had the
involvement of both the jawbones. All these patients were
subclassiﬁed according to the staging system proposed by the
AAOMS in the following groups: Stage I (34/190), Stage II
(126/190), and Stage III (30/190) (Table 1).
Treated sites were 166, 38 in noncancer patients and 128
in cancer patients.
Inclusion criteria for treatment were presence of exposed
or unexposed symptomatic BRONJ.
Incisional biopsy was performed independently from
surgical procedure for BRONJ for lesions suspected to be
manifestations of primary disease: specimen of every BRONJ
lesions were extracted for histological evaluation.
Patients satisfying inclusion criteria but presenting a very
poor health condition or mandibular fracture or diﬀused
Stage III BRONJ not treatable under local anaesthesia were
not included in the present evaluation; lack of consent to
surgery was also an exclusion criteria for these patients.
An orthopantomography (OPT) and a CT scan of the
lesion were obtained in all cases.
In each case the ﬁrst therapeutic approach was chosen
on the basis of the most updated guidelines available at the
time of treatment. Surgical approach was taken into account
afterthreeconsecutiveantibioticcyclesnotleadingtoastable
improvement of BRONJ. Each surgical intervention was
performed under local anaesthesia and planned according to
the extension of the lesion: limited or extensive treatments
have been performed with the same kind of approach for
both laser-assisted and nonlaser-assisted protocols. In all
surgical cases, mucoperiosteal ﬂaps were elevated to visualize
andremovethenecroticbone.Surgicalinstrumentsincluded
conventional bone burs or Er:YAG laser. A complete closure
of the surgical wound was performed through conventional
sutures.
In addition to antibiotic or surgical treatment in two
separate groups we performed LLLT applications using
Nd:YAG laser. According to the ethical standards of the Aca-
demic Hospital of Parma, we obtained a speciﬁc informed
consensus for each patient.
Each patient was treated according a speciﬁc protocol
(Table 3) as follows.
G1: BRONJ sites treated only with antibiotic therapy
(oral amoxicillin 1gr2times/day with oral metronidazole
250mg2times/day) for two weeks. Mouthwashes with
chlorhexidine (0.20%) and hydrogen peroxide (3%) were
also prescribed two/three times a day, sometimes with
antimycotic rinses.
G2: BRONJ sites treated with antibiotic therapy (as
describedinG1)andLLLT.Inparticular,eachlesionreceived
LLLT applications once a week for two months. Each LLLT
application was performed with Nd:YAG Laser (1064nm,
Fidelis Plus, Fotona, Slovenia) used at 1.25W power, 15Hz
frequency, very short pulse mode (VSP) and 320µmo fﬁ b r e
diameter. The laser light was used in a nonfocused way with
a scanning method, 2mm from tissue, for 1 minute (power
density: 268.81W/cm2, ﬂuence: 14.37J/cm2)a n dr e p e a t e d
5t i m e s[ 14]: this kind of protocol has been tested for
thermal changes on bone and soft tissues without funding
any damage depending by thermal elevation [15].
G3: BRONJ sites treated with antibiotic and tradi-
tional surgical therapy. In this group antibiotic treatmentJournal of Osteoporosis 3
Table 2: Risk factors: smoking habits, diabetes, hypertension, heart disease comprehending coagulation disorders, liver disease, and
corticosteroids administration; BM: bone metastasis, MM: multiple myeloma, OP: osteoporosis and/or rheumatoid arthritis.
Primary disease Patients number Smoking habits Diabetes Hypertension Heart disease Liver disease Corticosteroids
BM 85 25 10 24 21 2 69
MM 7 6 17 10 2 38 38
OP 43 7 6 18 6 1 18





(0.20%) and hydrogen peroxide (3%) two/three times a day.
G2 Medical therapy + LLLT
G1 protocol + LLLT applications once a week for two months with
Nd:YAG Laser (1.25W, 15Hz, VSP, 320µm) of ﬁbre diameter, nonfo-
cused way with scanning method, 2mm from tissue, for 1 minute and
repeated 5 times.
G3 Traditional surgery
Antibiotic treatment prescribed beginning three days prior to the opera-
tion and ending 10 days after it. Conservative surgical treatments using
traditional surgical instruments consisted in sequestrectomy of necrotic
bone or superﬁcial debridement/curettage or corticotomy/surgical
removal of alveolar and/or cortical bone.
G4 Traditional surgery + LLLT
G3 protocol + LLLT applications once a week for two months with
Nd:YAG Laser (1.25W, 15Hz, VSP, 320µm) of ﬁbre diameter, nonfo-
cused way with scanning method, 2mm from tissue, for 1 minute and
repeated 5 times.
G5 Er:YAG laser surgery
Antibiotic treatment prescribed beginning three days prior to the
operation and ending 10 days after it. Bone resection or vaporization
of the necrotic areas was obtained with Er:YAG laser with variable
parameters, from 250mJ 20Hz (VSP) with a ﬂuence of 50J/cm2 up to
300mJ, 30Hz and ﬂuence of 60J/cm2.
Figure 1: Stage III BRONJ in a female patient treated with
alendronate for osteoporosis.
was usually prescribed beginning three days prior to the
operation and ending 10 days after it. Conservative (and,
when possible, early) surgical treatments were reserved for
these lesions consisting in (a) sequestrectomy of necrotic
bone, (b) superﬁcial debridement/curettage and (c) corti-
cotomy/surgical removal of alveolar and/or cortical bone.
Operations wereperformedusing traditional surgicalinstru-
ments: cold blade scalpel to incise mucosal tissues and rotary
cutting instruments to remove necrotic bone.
G4: BRONJ sites treated with antibiotic, traditional
surgical therapy, and LLLT. Sites were treated with medical
and surgical therapy in association with LLLT (Nd:YAG
laser) applications. Surgical operations were performed as
described in G3 in association with laser Nd:YAG biostim-
ulation (1.25W power, 15Hz frequency, ﬁbre of 320µm).
The laser light was used as described in G2. The ﬁrst
application of LLLT was performed during the surgical
intervention. The operated site was then treated every week
with LLLT applications (same protocol described for G2) for
2 months.
G5: BRONJ sites treated with antibiotic, Er:YAG laser
surgical therapy, and LLLT. Surgical removal of necrotic and
peripherical bone was achieved with Er:YAG laser. Bone
resection or vaporization of the necrotic areas was obtained
with variable parameters, from 250mJ 20Hz (VSP) with
aﬂ u e n c eo f5 0J / c m 2 up to 300mJ, 30Hz and ﬂuence
of 60J/cm2. During the surgical intervention we used as
irrigation a iodopovidone solution; Er:YAG laser device has
been used with a distilled water irrigation system (Figures 1,
2, 3, 4, 5, 6, 7,a n d8)[ 16].
Results were evaluated by comparing the performed
treatments in cancer and non cancer groups; statistical
analysis was performed using Fisher test, and results were
considered statistically signiﬁcant for P<0.05.4 Journal of Osteoporosis
Figure 2: CT image of patient’s maxilla showing sinusitis for
maxillary sinus involvement by BRONJ disease.
Figure 3: Bone resection and corticotomy with Er:YAG laser
(Step 1): necrotic aspect of the bone is visible.
3. Results
Nonsurgical approach adopted on 69 sites induced an
improvement in 35 sites (50.7%) and complete healing in 19
sites (27.5%), while surgical approach performed on 97 sites
induced an improvement in 84 sites (86.6%), of which, 78
completely healed (80.41% of the total).
Improvement was recorded in 31 out of the 38 (81.5%)
BRONJ sites treated in non cancer patients and in 88 out of
128 (68.75%) sites in cancer patients. Complete healing was
recorded in 27 out of 38 (71.5%) BRONJ sites treated in non
cancer patients and in 69 out of 128 (53.9%) sites in cancer
patients.
Results in terms of clinical improvement and complete
healing are reported in Tables 4, 5, 6,a n d7 for both groups
of patients. The mean follow-up was 16.44 ± 10.95 months
(ranging from 6 to 54).
Figure 4: Bone resection and corticotomy with Er:YAG laser
(Step 2): Er:YAG laser vaporization of bone with mirror handpiece
(R02) used at distance; visible is the sinus involvement.
Figure 5: Intraoperatory biostimulation (Step 3): before suturing,
Nd:YAG laser biostimulation was performed with a 320 microme-
ters ﬁber for 5 applications of 1 minute each.
Figure 6: Clinical image of thetreated site1 week after surgerywith
maintenance of suture.
For non cancer patients, a statistically signiﬁcant result
in terms of improvement was recorded from the comparison
between BRONJ sites treated with antibiotic therapy alone
(G1)andsitestreatedwithlocalLLLTapplications(G2)(P =
0.0031). Moreover, in this group of patients, the comparison
between non surgical (G1+G2) and surgical (G3+G4+G5)
approach conﬁrmed a statistically signiﬁcant result in terms
of both clinical improvement (P = 0.0080) and healing (P<
0.0001) (Table 4).Journal of Osteoporosis 5
Table 4: Clinical results and statistical analysis in noncancer patients in terms of clinical improvement and complete healing. Statistical
analysis in cancer patients: comparison between nonsurgical nonlaser-assisted approach (G1) and nonsurgical laser-assisted approach (G2)
and comparison between nonsurgical approach (G1 +G2) and surgical approach (G3 + G4 +G5).
Treatment Sites Improvement % Healing %
G1 Medical therapy 10 3 30 2 20
G2 Medical therapy + LLLT 9 9 100 5 55.5
G3 Traditional surgery 4 4 100 4 100
G4 Traditional surgery + LLLT 5 5 100 5 100
G5 Er:YAG laser surgery 10 10 100 10 100
G1 versus G2 P = 0.0031 P = 0.1698
G1 + G2 versus G3 + G4 + G5 P = 0.0080 P<0.0001
Table 5: Clinical results and statistical analysis in cancer patients in terms of clinical improvement and complete healing. Statistical analysis
in cancer patients: comparison between nonsurgical nonlaser-assisted approach (G1) and nonsurgical laser-assisted approach (G2) and
comparison between nonsurgical approach (G1 + G2) and surgical approach (G3 +G4 + G5).
Treatment Sites Improvement % Healing %
G1 Medical therapy 22 5 22.7 4 18.2
G2 Medical therapy + LLLT 28 18 64.3 6 21.4
G3 Traditional surgery 13 7 53.8 7 53.8
G4 Traditional surgery + LLLT 34 28 82.3 24 70.6
G5 Er:YAG laser surgery 31 30 96.8 28 90.3
G1 versus G2 P = 0.0046 P = 1
G1 + G2 versus G3 + G4 + G5 P<0.0001 P<0.0001
G3 versus G4 +G5 P = 0.0061 P = 0.0726
Figure 7:Clinicalimagewithpersistenceofcompletehealing1year
after surgery.
For cancer patients a statistically signiﬁcant diﬀerence in
terms of improvement was recorded when the BRONJ sites
treated with antibiotic therapy alone (G1) were compared
to those treated with local LLLT applications (G2) (P =
0.0046). Moreover, in this group of patients, the comparison
between non surgical (G1 + G2) and surgical (G3 + G4 +
G5) approach reported a statistically signiﬁcant diﬀerence
in terms of both clinical improvement (P<0.0001) and
healing (P<0.0001). The comparison between surgical
Figure 8: CT images showing the improvement and the healing of
the maxillary sinus after the BRONJ treatment.
group without LLLT (G3) and surgical groups with LLLT
(G4 + G5) highlighted a statistically signiﬁcant results in
terms of clinical improvement (P = 0.0061) (Table 5).
The comparison between the performed treatment in
cancer and non cancer patients showed a signiﬁcant dif-
ference in terms of complete healing for surgical approach
(G3 +G4+G5) (P = 0.200).6 Journal of Osteoporosis
Table 6: Improvement and healing in relation with primary disease and BRONJ stage independently by the therapy (BM: bone metastasis,
MM: multiple myeloma, OP: osteoporosis and/or rheumatoid arthritis).
Primary disease Stage Number of sites Improvement (%) Healing (%)
BM
I 18 14 (77%) 14 (77%)
II 48 37 (77%) 25 (52%)
III 3 0 (0%) 0 (0%)
MM
I 12 9 (75%) 8 (66.6%)
II 44 28 (63.6%) 22 (50%)
III 3 0 (0%) 0 (0%)
OP
I 6 5 (83.3%) 5 (83.3%)
II 26 22 (84.6%) 17 (65.4%)
III 6 4 (66.6%) 4 (66.6%)
Table 7: Improvement and healing in relation with BRONJ stage independently by the primary disease.
BRONJ stage Treatment Sites Improvement (%) Healing (%)
Stage I




G2 6 3 (50%) 3 (50%)
G3 3 3 (100%) 3 (100%)
G4 7 5 (71.4%) 4 (57.2%)
G5 16 16 (100%) 16 (100%)
Stage II




G2 30 24 (80%) 8 (26.6%)
G3 13 8 (61.5%) 8 (61.5%)
G4 32 28 (87.5%) 25 (78.12%)
G5 21 20 (95.2%) 18 (85.7%)
Stage III
G1 6 0 (0%)
4 (33.3%)
0( 0 % )
4 (33.3%)
G2 1 0 (0%) 0 (0%)
G3 1 0 (0%) 0 (0%)
G4 — — —
G5 4 4 (100%) 4 (100%)
4. Discussion
Minimally invasive surgical approach with Er:YAG laser and
theuseofLLLTrepresentagoodchoiceforBRONJtreatment
especially for antibacterial and biostimulant properties.
Surgery performed with Er:YAG and followed by laser bios-
timulation (LLLT) may determine complete mucosal healing
andreducethemicrobialcomponent,thusdecreasingpatient
symptoms and providing a higher level of quality of life.
Moreover, Er:YAG laser surgery allows partial or total
resection of the jaw without using conventional rotary
cutting tools. Preservative surgery can also be performed by
gradual vaporization of necrotic bone at increasing depths.
Surgical ablation of bone tissue is performed reducing
the thermal damage to the adjacent tissue with a quicker
healing. The Er:YAG wavelength does not cause coagulation
orcarbonization.Itisthereforepossibletoclearlydistinguish
avascular portions of the bone from those that are still
vascularised. The Er:YAG laser has great potential for hard
tissue treatment due to its high absorption by both water
and hydroxyapatite. Such a device provides a clean and
precise cut with minimal injury to the adjacent hard and soft
tissues while producing an ablated surface favorable for cell
attachment.
Conservative surgery,maintaining the overall integrity of
the jawbone, is chosen on the basis of speciﬁc features in
individual cases, ranging from simple curettage to debride-
ment of the necrotic area, from sequestrectomy to resection
of larger bone portions. The mini-invasive technique of
ablation of the necrotic bone usually induces resurface and
causes bleeding from healthy bone which could help in the
future revascularization.
Asalreadyreportedinliterature[17,18],medicaltherapy
alone induces only little improvement of BRONJ lesions in
both cancer and non cancer patients.
In nonsurgical-treated patients in both evaluated groups,
LLLT applications induced a higher improvement of BRONJ
suggesting that the application of LLLT can be useful,
especially for patients that cannot be treated surgically.
A statistically signiﬁcant diﬀerence was observed for
surgical approach, both for a complete mucosal healing and
for a clinical improvement.
The evaluation of the percentage of the sites, with
clinicalhealingachievedwiththediﬀerenttreatments,clearlyJournal of Osteoporosis 7
showed how the combination of antibiotic therapy, conser-
vative surgery, and LLLT applications gives better results in
both groups of patients.
From our experience, medical approach alone (antibiotic
therapy) does not provide permanent clinical outcomes.
Symptomsimprovementandcompletemucosalhealingwere
obtained in 22.7% and 18.2% in cancer patients and in
30% and 20% in osteoporotic patients. Surgical approach
performed in early stages of BRONJ induces better results
between 53.8% and 100%.
Osteoporotic patients obtained higher levels of improve-
ment with every approach; surgical therapy with or without
laser induced complete mucosal healing in all cases (100%).
For cancer patients Er:YAG laser surgery induced com-
pleteremissionofBRONJinastatisticallysigniﬁcantnumber
of cases (90.3% versus 53.8% obtained with traditional
surgery) (Tables 4 and 5); as reported in literature [19–21],
this technique allows a mininvasive surgery probably related
to the good results of this approach in BRONJ treatment.
Angiero et al. [19], Scoletta et al. [22], and Romeo
et al. [23] reported the usefulness of laser biostimulation
in BRONJ. Our experience conﬁrms that LLLT in both
categories cancer and osteoporotic patients can oﬀer great
results in terms of reduction of inﬂammation and pain
c o n t r o la sw ea l r e a d yr e p o r t e d[ 24, 25].
Independently by the performed therapy, the percentage
ofcompleteBRONJhealingwasrelatedtothestageofdisease
(Table 7): 75% Stage I, 54.24% Stage II, and 33.3% Stage III.
In conclusion an early conservative surgical approach
with Er:YAG laser combined with LLLT, for BRONJ, could
be considered as more eﬃcient in comparison to medical
therapy alone for the management and quality of life of these
patients.
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